Vishal Sikri - 23 Feb 2024 Form 4 Insider Report for NEOGENOMICS INC (NEO)

Role
President Advanced Diagnostics
Signature
/s/ Ali Olivo, Attorney-in-Fact
Issuer symbol
NEO
Transactions as of
23 Feb 2024
Net transactions value
$0
Form type
4
Filing time
27 Feb 2024, 16:27:34 UTC
Previous filing
02 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NEO Common Stock 128,921 23 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NEO Stock Option (Right to Buy) Award $0 +42,344 $0.000000 42,344 23 Feb 2024 Common Stock 42,344 $16.45 Direct F8
transaction NEO Restricted Stock Unit Award $0 +25,329 $0.000000 25,329 23 Feb 2024 Common Stock 25,329 $0.000000 Direct F6, F9
transaction NEO Performance Stock Unit Award $0 +25,330 $0.000000 25,330 23 Feb 2024 Common Stock 25,330 $0.000000 Direct F6, F10
holding NEO Stock Option (Right to Buy) 319,112 23 Feb 2024 Common Stock 319,112 $8.42 Direct F2, F3
holding NEO Stock Option (Right to Buy) 39,683 23 Feb 2024 Common Stock 39,683 $19.65 Direct F4
holding NEO Restricted Stock Unit 21,204 23 Feb 2024 Common Stock 21,204 $0.000000 Direct F5, F6
holding NEO Performance Stock Unit 21,204 23 Feb 2024 Common Stock 21,204 $0.000000 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This balance includes 1,205 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3.
F2 On June 1, 2022, Mr. Sikri was granted 193,799 stock options. These options vest ratably over the first two anniversary dates of the grant date.
F3 On June 1, 2022, Mr. Sikri was granted 125,313 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F4 On May 11, 2023, Mr. Sikri was granted 39,683 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F5 On May 11, 2023, Mr. Sikri was granted 21,204 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F6 Once vested, the shares of common stock are not subject to expiration.
F7 On May 11, 2023, Mr. Sikri was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
F8 On February 23, 2024, Mr. Sikri was granted 42,344 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F9 On February 23, 2024, Mr. Sikri was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F10 On February 23, 2024, Mr. Sikri was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.